Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9), a major regulator of cholesterol homeostasis, is associated with glucose metabolism. Liraglutide, a glucagon-like peptide-1 receptor agonist, can increase insulin secretion in a glucose-dependent manner and lower blood glucose. We ai...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cardiovasc Diabetol
Glavni autori: Yang, Sheng-Hua, Xu, Rui-Xia, Cui, Chuan-Jue, Wang, Yin, Du, Ying, Chen, Zhi-Guo, Yao, Yu-Hong, Ma, Chun-Yan, Zhu, Cheng-Gang, Guo, Yuan-Lin, Wu, Na-Qiong, Sun, Jing, Chen, Bu-Xing, Li, Jian-Jun
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2018
Teme:
Original Investigation
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5885408/
https://ncbi.nlm.nih.gov/pubmed/29618348
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-018-0689-9
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items